ArticlemBio2019
Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex.
Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Article
- Potent Monoclonal Antibodies Against Circulating Yellow Fever Virus Strains from Donors Immunized with the 17D Vaccine.The American journal of tropical medicine and hygiene · 2026Article
- Review
- Two mutations in NS2B are responsible for attenuation of the yellow fever virus (YFV) vaccine strain 17D.PLoS pathogens · 2025Article
- West Nile virus unmasked: from gene variability to future challenges.Frontiers in cellular and infection microbiology · 2025Review
- Parallel Multifactorial Process Optimization and Intensification for High-Yield Production of Live YF17D-Vectored Zika Vaccine.Vaccines · 2024Article
- Article
- Replication Kinetics of a Candidate Live-Attenuated Vaccine for Cache Valley Virus inVector borne and zoonotic diseases (Larchmont, N.Y.) · 2022Article
- Evaluation of Whatman FTA cards for the preservation of yellow fever virus RNA for use in molecular diagnostics.PLoS neglected tropical diseases · 2022Article
- Impact of yellow fever virus envelope protein on wild-type and vaccine epitopes and tissue tropism.NPJ vaccines · 2022Article
- Article
- Intra-Host Diversity of Dengue Virus in Mosquito Vectors.Frontiers in cellular and infection microbiology · 2022Review
- Japanese encephalitis virus live attenuated vaccine strains display altered immunogenicity, virulence and genetic diversity.NPJ vaccines · 2021Article
- Article
- Flavivirus: From Structure to Therapeutics Development.Life (Basel, Switzerland) · 2021Review
- Flavivirus NS1 and Its Potential in Vaccine Development.Vaccines · 2021Review
- Testing the genomic stability of the Brazilian yellow fever vaccine strain using next-generation sequencing data.Interface focus · 2021Article
- Attenuated dengue viruses are genetically more diverse than their respective wild-type parents.NPJ vaccines · 2021Article
- Genomic diversity contributes to the neuroinvasiveness of the Yellow fever French neurotropic vaccine.NPJ vaccines · 2021Article
- Uncovering patterns of the evolution of genomic sequence entropy and complexity.Molecular genetics and genomics : MGG · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
The molecular basis of attenuation for live-attenuated vaccines is poorly understood. The yellow fever (YF) 17D vaccine virus was derived from the wild-type, parental strain Asibi virus by serial passage in chicken tissue and has proven to be a very safe and efficacious vaccine. We have previously shown that wild-type Asibi is a typical RNA virus with high genetic diversity, while the 17D vaccine virus has very little genetic diversity. To investigate this further, we treated Asibi and 17D viruses with ribavirin, a GTP analog with strong antiviral activity that increases levels of mutations in the viral genome. As expected, ribavirin treatment introduced mutations into the Asibi virus genome at a very high frequency and decreased viral infectivity while, in contrast, the 17D vaccine virus was resistant to ribavirin, as treatment with the antiviral introduced very few mutations into the genome, and viral infectivity was not lost. The results were confirmed for another YF wild-type parental and vaccine pair, a wild-type French viscerotropic virus and French neurotropic vaccine. Using recombinant Asibi and 17D viruses, ribavirin sensitivity was located to viral nonstructural genes. Thus, two live-attenuated YF vaccine viruses are genetically stable even under intense mutagenic pressure, suggesting that attenuation of live-attenuated YF vaccines is due, at least in part, to fidelity of the replication complex resulting in high genetic stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.